MOTS-c

What It Is

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded within the mitochondrial genome. It is one of the few known mitochondria-derived peptides (MDPs) with systemic signaling activity. Research has demonstrated its role in metabolic regulation, exercise mimicry, and insulin sensitivity. Circulating MOTS-c levels decline measurably with age, placing it at the forefront of longevity research in 2026. A 2025 study published in Experimental & Molecular Medicine demonstrated that MOTS-c prevents pancreatic islet cell senescence by modifying senescence-associated transcriptional and metabolic profiles in β-cells, delaying diabetes progression in animal models. A separate 2025 study in Frontiers in Physiology showed MOTS-c restores mitochondrial respiration in type 2 diabetic heart tissue, expanding its therapeutic relevance to cardiovascular metabolic disease. In sedentary animal models, exogenous MOTS-c reproduced training-induced metabolic adaptations, earning it the label 'exercise mimetic peptide.' Updated research confirms skeletal muscle MOTS-c levels increase nearly 12-fold during exercise. Exogenous MOTS-c doubled running capacity in mice and reversed age-related physical decline by activating the AMPK/PGC-1α pathway and directly binding casein kinase 2 (CK2). Notably, circulating MOTS-c levels are significantly higher in centenarian populations compared to age-matched controls, suggesting maintained MOTS-c signaling may serve as both a biomarker and driver of successful metabolic aging. A key challenge for clinical translation is MOTS-c's low bioavailability, poor stability, and short half-life — limitations common to mitochondrial-derived peptides that have slowed clinical development. As of April 2026, no active MOTS-c human trials are registered on ClinicalTrials.gov, though a trial using a MOTS-c analog for fatty liver and obesity (NCT03998514) has been registered. MOTS-c is scheduled for PCAC review on July 23, 2026, alongside BPC-157, KPV, and TB-500, to determine whether it can be legally compounded under section 503A. A 2026 study in ScienceDirect examined MOTS-c's role in type 2 diabetes mellitus complications including cardiovascular disease, establishing MOTS-c as a multi-organ protective factor whose deficiency correlates with cardiometabolic risk. Public comments via docket FDA-2025-N-6895 are accepted until July 22, 2026.

Regulatory Status

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how MOTS-c compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] Lee C. et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab. 2015 PubMed
2. [2] MOTS-c prevents pancreatic islet cell senescence to delay diabetes — Exp Mol Med. 2025 PubMed
3. [3] MOTS-c restores mitochondrial respiration in type 2 diabetic heart — Frontiers Physiol. 2025 PubMed
4. [4] MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline — Nature Commun. 2021 PubMed
5. [5] MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications — Life Sciences 2026 PubMed
6. [6] FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee PubMed

Related Peptides